Business
Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021
AUSTIN, Texas, April 1, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of
About this update from Spyre Therapeutics, Inc.
[{"type":"text","content":"AUSTIN, Texas, April 1, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced it will participate in two virtual investor conferences in April 2021. \nConference Details\nConference Name: 2021 Virtual Wells Fargo Biotech Corporate Access DayConference Date: Tuesday, April 6 and Thursday, April 8Participants: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea's president and chief executive officer and Michael C. Hanley, Aeglea's chief commercial officer\nConference Name: 20th Annual Needham Virtual Healthcare Conference Conference Date: Monday, April 12 through Thursday, April 15Presentation Date and Time: Tuesday, April 13 at 11:00 am ETPresenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea's president and chief executive officerWebcast: https://ir.aeglea.com/events-and-presentations/ \nTo access the live and archived webcast, visit the Events & Presentations section of the Company's website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. A replay of the webcast will be available through the Company's website for 30 days thereafter.\nAbout Aeglea BioTherapeutics\nAeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. The Company initiated a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria in 2020. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have big impact on the lives of patients and their families. For more information, please visit http://aeglea.com.\n\n \n\n\n\n View original content to download multimedia:http://www.prnewswire.com/news-releases/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021-301261051.html\nSOURCE Aeglea BioTherapeutics, Inc.","length":43...